“The Terasaki Institute leads the world in the development of bioprintable, biopolymer-based technologies poised to revolutionize drug delivery, wearable and implantable devices. Jointly with HTL we expect to bring to life a new generation of biopolymer-based applications in critical sectors of precision and regenerative medicine,” added Maurizio Vecchione, Chief Innovation Officer of the Terasaki Institute for Biomedical Innovation.
Read more below.
To see our most recent news,
![](https://htlbiotech.com/wp-content/uploads/2023/08/partner-1.jpg)
Read more
news from us
-
Articles July 5, 2024
HTL Biotechnology Secures Medical Device Registration in China
Sodium DNA Raw Material Main Document (Polynucleotides) registered as a medical device (number M2024199-000) in China.
-
Articles June 21, 2024
HTL Biotechnology at CPHI China 2024
CPHI China is one of Asia’s leading Pharma events for trading and networking with 3,500+ exhibitors and 90,000+ professionals from the pharmaceutical industry,
-
Articles June 13, 2024
Discover our Quality Policy
At HTL Biotechnology, we believe in going beyond together to achieve the highest quality standards.